trending Market Intelligence /marketintelligence/en/news-insights/trending/H6D6kh9ACumMXgo-KJ5_zg2 content esgSubNav
In This List

Novartis drug prolongs time to patients' first sickle cell pain crisis in study

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Novartis drug prolongs time to patients' first sickle cell pain crisis in study

Novartis AG drug crizanlizumab delayed the time to first sickle cell pain crisis in patients versus placebo in key subgroups of adult patients with sickle cell disease in a phase 2 trial.

Acute sickle cell pain crises are a common painful complication of the disease and the main reason that patients seek medical care in hospitals. They are also known as vaso-occlusive crises.

The data will help support discussions with regulatory agencies, with filing expected in the U.S. by the end of 2018.